|
While thousands of bird flu viruses are in circulation at any given time and do not immediately threaten human populations, HPAI H5N1 is an exception. H5N1 has caused 357 severe human disease cases and 223 deaths as of January 29, 2008. H5N1 crossed the species barrier to humans in 1997 and 2003 (Hong Kong) and since December 2003 worldwide. Another concern with H5N1 is its potential to instigate another influenza pandemic. So far, the virus has met all prerequisites for a pandemic save one: the ability to spread efficiently and sustainably among humans. Most scientists agree that another pandemic is inevitable; however, whether it is with H5N1 remains to be determined.
Close contact with dead or sick birds is the principal source of human infection with H5N1. Particularly high-risk behaviors include the slaughtering, de-feathering, butchering and preparation of infected birds for consumption. In nearly one quarter of reported cases, the exact source of exposure is unclear, leading many to believe that environment-to-human transmission is likely. Exposure to chicken feces by children playing in a poultry area and exposure to infected water bodies are two concerning potential sources.
Programmatic Considerations
Vaccines and antivirals are important considerations for AI prevention and response. Some antiviral drugs, notably oseltamivir (commercially known as Tamiflu®), may reduce the duration of viral replication and improve prospects of survival, if administered within 48 hours following symptom onset; however, efficacy is not fully known. Evidence of resistance is also emerging4. Comprehensive clinical studies demonstrating effectiveness against H5N1 have not been conducted. While efforts to produce a pre-pandemic vaccine for humans effective against avian influenza A (H5N1) viruses are ongoing, few H5N1 vaccines are currently available for human use. A vaccine produced by Sanofi is currently licensed in the United States and trials are underway for additional human H5N1 vaccines that may be licensed in the U.S. and abroad. Vaccine and antiviral availability, distribution, ethics and access issues must all be considered carefully on a country-basis in planning for AI response and pandemic preparedness.
Prioritizing AI prevention and response in resource-poor settings can be challenging. It may be advantageous to position AI as a ‘dual’ or ‘triple benefit’ program. AI can be a catalyst to improving national hygiene improvement programs for example, targeted at mediation of sanitation-based diseases. Such ‘readiness’ for one type of public health threat can translate into tangible improvements in overall public health infrastructure. It may be beneficial to identify other local communicable disease threats in addition to avian flu, assess shared H5N1 transmission routes (e.g. typhoid fever, hepatitis A, diarrhea), and tackle both simultaneously. Another option is to integrate AI risk communication into existing national- and community-based risk communication frameworks. By preparing communities, districts, and countries to identify and properly respond to animal and human outbreaks, a country will be better prepared for other emergencies including, but not limited to, a pandemic.
Lessons Learned
References:
1 E.g. ducks, gulls, and shorebirds
2 E.g. chickens, turkeys, ducks, and geese
3 Pathogenicity refers to the ability of the virus to produce disease.
4 http://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/avian_pandemic_flu/content/2007/2007-08-10-studyh5n1showingincreasedresistance.html
5 See http://www.unicef.org/avianflu/index.html for more information.
Other technical briefs can be found at: www.maqweb.org/techbriefs/index.shtml
Last revised: 2/21/08
Produced in association with The Maximizing Access and Quality Initiative
Designed and produced by: The INFO Project at the Johns Hopkins Bloomberg School of Public Health/Center for Communication Programs.
Published with support from the United States Agency for International Development (USAID), Global, GH/PRH/PEC, under the terms of Grant No. GPH-A-00-02-00003-00.
|
Maximizing Access and Quality (MAQ) Initiative Site maintained by The INFO Project E-mail: webmaster@maqweb.org Security and Privacy Policy Disclaimer: The information provided on this web site is not official U.S. Government information and does not represent the views or positions of the U.S. Agency for International Development or the U.S. Government. |
![]() |